Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
|Headquarters||New York, New York|
|Number of employees||51-200 employees|
Top 5 Recent Tweets
|July 28, 2022||CureNETs||If you missed our 2022 KNOW YOUR NETs Conference you can stream the entire conference here https://t.co/knSF6AXzLa… https://t.co/3qTUNkLauG|
|July 28, 2022||ProgenicsCB||Unique Banking Technique & Storage
EquipmentAll of our equipment meet the highest quality standards.… https://t.co/fMi86zQlMn
|July 26, 2022||urotoday||Tumor Board reviewing locally adv pT3N1M0 #ProstateCancer. @CaPsurvivorship is joined by Andrei Iagaru, @geoffsonn… https://t.co/ABRm2TsmqS|